Iricip 100mg Injection contains Irinotecan, a chemotherapeutic agent classified as a topoisomerase I inhibitor, indicated primarily for the treatment of metastatic colorectal cancer. Irinotecan exerts its antineoplastic effect by inhibiting the enzyme topoisomerase I, which is essential for DNA replication and transcription, thereby inducing DNA damage and apoptosis in rapidly dividing cancer cells. Iricip is administered intravenously, typically as part of combination chemotherapy regimens such as FOLFIRI (irinotecan, fluorouracil, and leucovorin). The dosage and treatment schedule should be individualized based on patient tolerance, tumor response, and hematologic parameters. Common adverse effects include neutropenia, diarrhea (which may be early-onset cholinergic or late-onset secretory), nausea, vomiting, and fatigue. Premedication with antiemetics and atropine may be required to manage side effects. Close monitoring of blood counts and liver function tests is recommended during therapy. Iricip is contraindicated in patients with known hypersensitivity to irinotecan or its components and should be used with caution in patients with pre-existing gastrointestinal disorders or impaired hepatic function. This agent plays a critical role in improving survival outcomes in advanced colorectal cancer when used appropriately under oncologic supervision.